According to the contract research organization (CRO) Optimapharm, the acquisition of Denothex strengthens its presence in the European market, specifically in France, Germany, Switzerland, Spain, and Italy.
Switzerland headquartered Denothex is a CRO with operations across Europe and Israel with a focus on biotechnology and medical devices in oncology.
Established in Zagreb, Croatia in 2006, Optimapharm aims to become “one of the leading mid-size CRO companies in Europe.”
The company currently has offices in 14 European countries and opened its first US location in June 2018.
Optimapharm also acquired MKS Research in late 2017, at which time the company’s CEO Gordana Greguric Cicak told us he would continue looking for “good-quality acquisition targets.”
“Our goal is to consolidate the CRO market” in the Central and Eastern European Countries (CEE) as well as in South Eastern European (SEE) regions, he said.